ATAI · Atai Life Sciences N.V. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $749.0K | $719.0K | $1.55M | - | $40.0K | $273.0K | $0 | - | $87.0K | $172.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $14.68M | $11.09M | $11.33M | - | $12.38M | $12.61M | $11.53M | - | $13.29M | $15.48M |
| SG&A | $14.51M | $14.90M | $10.60M | - | $10.27M | $13.40M | $12.55M | - | $13.63M | $16.56M |
| Total Operating Expenses | $29.18M | $25.99M | $21.93M | - | $22.64M | $26.00M | $24.09M | - | $26.92M | $32.03M |
| D&A | $200.0K | $100.0K | $216.0K | - | - | - | $83.0K | - | - | - |
| Operating Income | ($28.44M) | ($25.27M) | ($20.37M) | - | ($22.60M) | ($25.73M) | ($24.09M) | - | ($26.83M) | ($31.86M) |
| Interest Expense | $0 | $702.0K | $687.0K | - | $686.0K | $702.0K | $687.0K | - | $686.0K | $0 |
| Income Tax | $131.0K | $93.0K | $156.0K | - | ($178.0K) | $19.0K | ($4.0K) | - | $238.0K | $185.0K |
| Net Income | ($61.07M) | ($27.73M) | ($26.43M) | - | ($26.29M) | ($57.31M) | ($26.71M) | - | $44.24M | ($33.04M) |
| EPS - Basic | ($0.28) | ($0.14) | ($0.15) | - | ($0.16) | ($0.36) | ($0.17) | - | $0.28 | ($0.21) |
| EPS - Diluted | ($0.28) | ($0.14) | ($0.15) | - | ($0.16) | ($0.36) | ($0.17) | - | $0.25 | ($0.21) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.40M | $61.94M | $48.29M | $17.50M | $29.96M | $19.33M | $18.87M | $45.03M | $76.49M | $141.09M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.37M | $4.04M | $2.71M | $2.62M | $4.88M | $3.81M | $3.84M | $4.59M | $5.51M | $3.86M |
| Current Assets | $130.67M | $102.68M | $115.98M | $80.13M | $114.07M | $117.91M | $117.50M | $185.59M | $215.82M | $242.77M |
| Total Assets | $239.82M | $189.20M | $195.78M | $159.39M | $197.52M | $215.78M | $269.12M | $293.48M | $308.22M | $253.59M |
| Current Liabilities | $16.54M | $25.55M | $28.50M | $24.95M | $19.64M | $17.64M | $15.01M | $20.12M | $19.70M | $17.93M |
| Long-term Debt | $0 | $0 | $9.30M | $14.13M | $20.34M | $15.24M | $15.14M | $15.05M | $14.96M | $14.87M |
| Total Liabilities | $79.91M | $45.28M | $43.51M | $42.83M | $51.20M | $47.24M | $45.86M | $49.16M | $39.71M | $37.96M |
| Stockholders' Equity | $159.75M | $143.74M | $152.05M | $116.30M | $145.72M | $167.89M | $222.54M | $242.96M | $266.28M | $212.55M |
| Retained Earnings | ($815.44M) | ($754.37M) | ($726.64M) | ($700.21M) | ($661.25M) | ($634.96M) | ($577.65M) | ($550.94M) | ($532.65M) | ($576.89M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($17.84M) | - | - | - | ($22.57M) | - | - | - |
| Investing Cash Flow | - | - | ($11.01M) | - | - | - | $11.47M | - | - | - |
| Financing Cash Flow | - | - | $59.60M | - | - | - | $0 | - | - | - |
| CapEx | - | - | $268.0K | - | - | - | $0 | - | - | - |
| Free Cash Flow | - | - | ($18.11M) | - | - | - | ($22.57M) | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -3796.5% | -3515.0% | -1310.0% | - | -56505.0% | -9424.5% | - | - | -30843.7% | -18524.4% |
| EBITDA margin | -3769.8% | -3501.1% | -1296.1% | - | - | - | - | - | - | - |
| Net margin | -8154.1% | -3856.6% | -1699.7% | - | -65715.0% | -20993.4% | - | - | 50855.2% | -19210.5% |
| Free cash flow margin | - | - | -1164.6% | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.69 | - | - | - | 0.85 | - | - | - |
| R&D / Revenue | 1959.9% | 1542.7% | 728.5% | - | 30942.5% | 4617.2% | - | - | 15275.9% | 8997.7% |
| SG&A / Revenue | 1936.6% | 2072.3% | 681.5% | - | 25662.5% | 4907.3% | - | - | 15667.8% | 9626.7% |
| Effective tax rate | - | - | - | - | - | - | - | - | 0.5% | - |
| Return on assets | -25.5% | -14.7% | -13.5% | - | -13.3% | -26.6% | -9.9% | - | 14.4% | -13.0% |
| Return on equity | -38.2% | -19.3% | -17.4% | - | -18.0% | -34.1% | -12.0% | - | 16.6% | -15.5% |
| Return on invested capital | -14.1% | -13.9% | -10.0% | - | -10.8% | -11.1% | -8.0% | - | -9.5% | -11.1% |
| Liquidity | ||||||||||
| Current ratio | 7.90 | 4.02 | 4.07 | 3.21 | 5.81 | 6.68 | 7.83 | 9.22 | 10.96 | 13.54 |
| Quick ratio | 7.90 | 4.02 | 4.07 | 3.21 | 5.81 | 6.68 | 7.83 | 9.22 | 10.96 | 13.54 |
| Cash ratio | 1.84 | 2.42 | 1.69 | 0.70 | 1.53 | 1.10 | 1.26 | 2.24 | 3.88 | 7.87 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | 0.06 | 0.12 | 0.14 | 0.09 | 0.07 | 0.06 | 0.06 | 0.07 |
| Debt / Assets | 0.00 | 0.00 | 0.05 | 0.09 | 0.10 | 0.07 | 0.06 | 0.05 | 0.05 | 0.06 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -36.0x | -29.7x | - | -32.9x | -36.7x | -35.1x | - | -39.1x | - |
| Equity multiplier | 1.50 | 1.32 | 1.29 | 1.37 | 1.36 | 1.29 | 1.21 | 1.21 | 1.16 | 1.19 |
| Liabilities / Assets | 0.33 | 0.24 | 0.22 | 0.27 | 0.26 | 0.22 | 0.17 | 0.17 | 0.13 | 0.15 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.01 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | 5.2x | - |
| P / B | 7.2x | 3.0x | 1.6x | - | 1.3x | 1.3x | 1.4x | - | 0.9x | 1.3x |
| P / S | 1536.9x | 598.7x | 154.2x | - | 4658.0x | 781.4x | - | - | 2632.9x | 1557.9x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1772.5% | 163.4% | - | - | -54.0% | 58.7% | -100.0% | - | 262.5% | 1.2% |
| Revenue CAGR (3y) | 214.8% | 61.7% | - | - | -46.8% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -25.8% | 1.8% | 15.4% | - | 15.8% | 19.2% | 27.5% | - | 30.2% | 9.9% |
| Net income growth (YoY) | -132.3% | 51.6% | 1.1% | - | - | -73.5% | 19.4% | - | - | 9.8% |
| EPS growth (YoY) | -75.0% | 61.1% | 11.8% | - | - | -71.4% | 19.0% | - | - | 12.5% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 19.8% | - | - | - | -5.5% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 9.6% | -14.4% | -31.7% | -52.1% | -45.3% | -21.0% | -6.0% | -6.8% | -8.0% | -31.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$308.0K totalReportable Segment Aggregation Before Other Operating Segment$308.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ATAI Life Sciences N.V. against the 5 most active filers in the same SIC group.